Amphastar Pharmaceuticals Inc. (AMPH)

18.78
0.25 1.31
NASDAQ : Health Technology
Prev Close 19.03
Open 18.99
Day Low/High 18.70 / 19.16
52 Wk Low/High 12.05 / 19.95
Volume 111.20K
Avg Volume 201.60K
Exchange NASDAQ
Shares Outstanding 45.98M
Market Cap 850.56M
EPS 0.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Amphastar Pharmaceuticals Reports Financial Results For The Three Months Ended September 30, 2017

Amphastar Pharmaceuticals Reports Financial Results For The Three Months Ended September 30, 2017

Reports Net Revenues of $57.9 Million for the Three Months Ended September 30, 2017

The 6 Medications Being Used to Tackle the Opioid Epidemic

The 6 Medications Being Used to Tackle the Opioid Epidemic

The U.S. opioid crisis rages on. TheStreet takes a look at several drugs being used to help treat people.

FDA OKs BioCryst's Rapivab for Pediatric Indication - Biotech Movers

FDA OKs BioCryst's Rapivab for Pediatric Indication - Biotech Movers

The approval marks "the first new influenza antiviral for pediatric use in over 10 years," said BioCryst president and CEO Jon Stonehouse in the news release.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: None Downgrades: ABAX, AMPH, CFG, CY, DDS, FNWB, MDLZ, OME, UEIC, WAB, WSTG Initiations: CERC, MEDP, WVE Read on to get TheStreet Quant Ratings' detailed report:

Amphastar Pharmaceuticals Reports Financial Results For The Three Months Ended June 30, 2017

Amphastar Pharmaceuticals Reports Financial Results For The Three Months Ended June 30, 2017

Reports Net Revenues of $65.2 Million for the Three Months Ended June 30, 2017

Oversold Conditions For Amphastar Pharmaceuticals (AMPH)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Amphastar Pharmaceuticals (AMPH) Shares Cross Below 200 DMA

In trading on Tuesday, shares of Amphastar Pharmaceuticals Inc crossed below their 200 day moving average of $17.02, changing hands as low as $16.90 per share. Amphastar Pharmaceuticals Inc shares are currently trading off about 2% on the day.

First Week Of August 18th Options Trading For Amphastar Pharmaceuticals (AMPH)

First Week Of August 18th Options Trading For Amphastar Pharmaceuticals (AMPH)

Investors in Amphastar Pharmaceuticals Inc saw new options begin trading this week, for the August 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AMPH options chain for the new August 18th contracts and identified one put and one call contract of particular interest.

Electronic Arts, Activision Blizzard and Take-Two Interactive: 'Mad Money' Lightning Round

Electronic Arts, Activision Blizzard and Take-Two Interactive: 'Mad Money' Lightning Round

Game on: Jim Cramer is bullish on Electronic Arts, Activision Blizzard and Take-Two Interactive.

Don't Let Stock Picking Scare You: Cramer's 'Mad Money' Recap (Wednesday 7/19/17)

Don't Let Stock Picking Scare You: Cramer's 'Mad Money' Recap (Wednesday 7/19/17)

Jim Cramer says do your homework, be informed and don't let the wise guys trip you up with their warnings about 'single-stock risk.'

Short Interest Moves 10.7% Lower For AMPH

Short Interest Moves 10.7% Lower For AMPH

The most recent short interest data has been released for the 06/30/2017 settlement date, which shows a 347,041 share decrease in total short interest for Amphastar Pharmaceuticals Inc , to 2,901,901, a decrease of 10.68% since 06/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Amphastar Pharmaceuticals Stock Sees Short Interest Increase 17.7%

The most recent short interest data has been released for the 06/15/2017 settlement date, which shows a 487,915 share increase in total short interest for Amphastar Pharmaceuticals Inc , to 3,248,942, an increase of 17.67% since 05/31/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AMPH, HRTG, JCAP, MIK, MTLS, NSM, TRU Downgrades: CFG, DGICB, EOCC, GILT Initiations: ENIC, GMS, MSBI, USFD, ZDGE Read on to get TheStreet Quant Ratings' detailed report:

Amphastar Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish for AMPH

In trading on Tuesday, shares of Amphastar Pharmaceuticals Inc crossed above their 200 day moving average of $17.22, changing hands as high as $17.66 per share. Amphastar Pharmaceuticals Inc shares are currently trading up about 4.1% on the day.

Amphastar Pharmaceuticals Reports Financial Results For The Three Months Ended March 31, 2017

Reports Net Revenues of $56.7 Million for the Three Months Ended March 31, 2017

DepoMed, Opioid Makers Fall After Trump's FDA Pick Says America's Drug Addiction Is Out of Control

DepoMed, Opioid Makers Fall After Trump's FDA Pick Says America's Drug Addiction Is Out of Control

Washington needs to do more, Gottlieb says at his confirmation hearing.

TheStreet Quant Rating: C (Hold)